Singapore-based medical testing firm Mirxes joins Jiangsu Hengrui Pharmaceuticals in revitalised market’s listing surge.

TopBuild excels in construction with strong Q1'25 results, disciplined management, and growth initiatives. Click to know if ...

Baron Opportunity Fund declined in Q1 2025, underperforming its benchmark. Who were the leaders and laggards? Click here to ...

Q1 2025 Earnings Call Transcript May 13, 2025 Gevo, Inc. beats earnings expectations. Reported EPS is $-0.09, expectations ...